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Abstract 
The protozoan parasite Histomonas meleagridis is the aetiological agent of histomonosis, a highly fatal disease in 
turkeys with less mortality in chickens. Following the ban of licensed drugs to be used for prophylactic and 
therapeutic treatment the number of outbreaks increased in recent years, without any suitable and legal option to 
combat the disease. In various cases the whole flock had to be killed in order to reduce suffering of animals 
highlighting the importance histomonosis has gained also in the light of animal welfare. Considering the difficulties 
for licensing new drugs to be used in food producing animals, vaccination would be a new option to combat the 
disease. In the following presentation the efforts are consecutively presented leading to a safe and efficient vaccine, 
without any side effects on health and performance of birds. This vaccine could be the basis to prevent suffering and 
loss of animals due to a non-treatable disease. 
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1. Introduction 
Histomonosis (syn. histomoniasis or blackhead disease) is a parasitic disease caused by the flagellated 
protozoon Histomonas meleagridis [1]. It is most harmful in turkeys with up to 100% mortality and a 
lower mortality in chickens [2]. Due to the actual drug legislation for food producing animals, 
prophylactic or therapeutic intervention is no longer possible within the EU and very much limited in the 
USA [3, 4, 5]. Consequently, numerous outbreaks occurred in recent years since the complete ban was 
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implemented in 2003. Searching for new drugs is hampered by possible side effects they may cause as 
demonstrated for the aminoglycoside antibiotic paromomycin [6]. According to this report of the 
European Food and Safety Authority, the drug selects for resistance and cross-resistance against other 
aminoglycosides among bacteria present in the gut, raising serious concerns. Because prophylaxis and 
therapy was performed over decades with chemical substances, vaccination would be a completely new 
approach to combat the disease. 
The lack of knowledge about the protozoan parasite H. meleagridis is a certain hindrance for vaccine 
development. Earlier studies had shown that the protozoan might survive only for a short time under 
adverse conditions [7]. Even after completion of a successful development this may limit the efficient 
application by mass vaccination technology like spray or drinking water, commonly used in poultry. 
Efficacy and safety of the vaccine without any negative influence on the general constitution of the bird 
are the most important parameters to be investigated prior to release of such a product. 
2. Materials and Methods 
Different animal trials were performed to address the likelihood of vaccination against histomonosis. 
All trials were accompanied with newly developed laboratory methods suitable to determine the presence 
of the H. meleagridis in tissues and excreted faeces. Recently established ELISA [8] was applied to 
confirm the infection and spread of the vaccine or challenge to in-contact birds. All trials were discussed 
and approved by the institutional ethics committee and licensed by Austrian law. The detailed description 
of every experiment can be found in the publications listed in the references. 
3. Results and Discussion 
The first step towards vaccine development was the establishment of a defined culture capable to be 
stored and preserved accordingly. Growing of numerous protozoa is influenced by certain factors and 
very often a complicated and cumbersome procedure [9]. To obtain a well defined culture of H. 
meleagridis micromanipulation was adopted, as this technology enables the selection of single cells [10]. 
For correct identification a nomenclature was introduced stating the type of protozoon/species of 
bird/country of origin/diagnostic number-clone number/year of isolation (Hm/Turkey/Austria/2922-
C6/04). A starter medium including defined bacteria was needed for optimal growth condition. Such 
xenic cultures can be frozen down in the presence of DMSO as cryoprotectant, enabling long term 
storage. In a first step such a culture was found highly virulent after a few passages, inducing 100% 
mortality and spread to in-contact birds [11]. 
Based on the known experience by attenuating other micro-organisms through long term passaging in 
vitro, aliquots of such a culture were passaged every 3-4 days. In the past several authors have reported 
divergent results performing such kind of investigations. As a consequence of this and based on own 
experiments Lund et al. [12] concluded that attenuation is not possible by performing in vitro passages. 
Instead such an outcome is the result of a selection process occurring in a culture which contains 
flagellates of different virulence. Based on our results this hypothesis could be contradicted by applying 
clonal cultures traced back to a single cell. Following 95 passages the parasites were already attenuated 
with no mortality in experimentally infected turkeys [13]. This process was even pronounced continuing 
in vitro cultivation for up to 295 passages. In the same study it could be shown that all birds which were 
previously infected with attenuated protozoa were completely protected against a severe challenge 4 
weeks post vaccination with virulent histomonads. Not only the vaccine, the virulent parasites as well 
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spread efficiently to in-contact birds. In comparison to the live parasites, killed histomonads injected 
intramuscularly were found non-protective. This is in agreement with an earlier study in which serum of 
surviving birds transmitted to susceptible animals was unable to protect these birds [14]. This was later 
confirmed by another group comparing active and passive immunization [15].  
Even though successful protection could be demonstrated in the initial study the application of the 
vaccine via the cloaca of the birds reflected a certain hindrance for mass application under field 
conditions. Similar to the results mentioned above Hu and McDougald [16] demonstrated that 
histomonads could be transmitted from infected to in-contact birds in the absence of any vector. A 
phenomenon described as cloacal drinking was given as possible explanation for the uptake of fragile 
parasites into the caeca. Performing constant re-isolation of histomonads from faeces we were able to 
demonstrate the successful spread of the flagellates already 2 days post infection, arguing for another 
route of transmission. Considering birds behaviour of constant picking at faeces the oral uptake of 
parasites seem to be the first choice. Consequently, oral infection was favoured in a separate study using 
virulent histomonads. The effective oral infection could be demonstrated in several experimental settings 
and the parasites spread again to in-contact birds. Birds were deprived from food and water for 5h 
following infection in order to increase efficiency of infection. The ability of H. meleagridis to induce 
cyst-like stages under in vitro conditions may contribute to the success of oral infection as these stages are 
more suitable to survive the harsh conditions within the digestive tract [17]. 
As a consequence of the above mentioned study it was obvious to investigate in a follow up 
experiment whether attenuated parasites can be used for oral vaccination. For this approach day-old 
turkeys were vaccinated in order to induce an early protection [18]. Birds kept in different groups were 
challenged either at 2 or 4 weeks post vaccination. Challenging of vaccinated birds at 2 weeks post 
vaccination induced partial protection as some birds died, whereas all birds which were challenged 4 
weeks post vaccination survived indicating complete protection. In a separate group birds were only 
vaccinated omitting any challenge. Weekly blood samples were taken to confirm infection which was 
noticed three weeks post vaccination based on presence of IgG. The antibodies stayed above the cut-off 
value until the study was terminated at 16 weeks post vaccination indicating the potential of the 
developed ELISA. In addition, non adverse effect on body weight gain could be noticed in these birds. 
In conclusion, a consecutive series of experiments was presented outlining the development of a live 
vaccine to protect turkeys from fatal histomonosis. Beside its efficacy the vaccine is safe and has no 
negative effect on performance. Therefore, for the first time it could be demonstrated that live vaccination 
based on clonal cultures is a new and suitable concept to prevent histomonosis in poultry avoiding any 
residues in meat products obtained from such birds. 
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